Characteristics of the study cohort
| Characteristic . | Value . |
|---|---|
| No. of patients | 2941 |
| Median age (range), y | 40.3 (0.6-71.6) |
| Diagnosis at transplantation, no. (%) | |
| Acute myeloid leukemia | 859 (29) |
| Acute lymphoid leukemia | 419 (14) |
| Chronic myeloid leukemia | 895 (30) |
| Myelodysplastic syndromes including myeloproliferative diseases | 504 (17) |
| Chronic lymphocytic leukemia and lymphomas | 191 (7) |
| Multiple myeloma | 73 (2) |
| Disease at transplantation, no. (%)* | |
| Low risk | 646 (22) |
| Standard risk | 1419 (48) |
| High risk | 877 (30) |
| Donor age, median (range), y | 38.6 (0.9-81.7) |
| Donor/patient sex, no. (%) | |
| Female/male | 722 (25) |
| Other | 2219 (75) |
| High-intensity conditioning regimens, no. (%) | |
| With TBI | 1730 (59) |
| Without TBI | 1137 (39) |
| With rabbit ATG | 74 (3) |
| GVHD prophylaxis, no. (%) | |
| Methotrexate with calcineurin inhibitors | 2394 (81) |
| Other | 547 (19) |
| Graft source, no. (%) | |
| Mobilized blood hematopoietic stem cells | 1014 (34) |
| Bone marrow | 1927 (66) |
| Donor type, no. (%) | |
| HLA-identical related | 1284 (44) |
| HLA-matched unrelated | 780 (26) |
| HLA-mismatched related | 270 (9) |
| HLA-mismatched unrelated | 607 (21) |
| Characteristic . | Value . |
|---|---|
| No. of patients | 2941 |
| Median age (range), y | 40.3 (0.6-71.6) |
| Diagnosis at transplantation, no. (%) | |
| Acute myeloid leukemia | 859 (29) |
| Acute lymphoid leukemia | 419 (14) |
| Chronic myeloid leukemia | 895 (30) |
| Myelodysplastic syndromes including myeloproliferative diseases | 504 (17) |
| Chronic lymphocytic leukemia and lymphomas | 191 (7) |
| Multiple myeloma | 73 (2) |
| Disease at transplantation, no. (%)* | |
| Low risk | 646 (22) |
| Standard risk | 1419 (48) |
| High risk | 877 (30) |
| Donor age, median (range), y | 38.6 (0.9-81.7) |
| Donor/patient sex, no. (%) | |
| Female/male | 722 (25) |
| Other | 2219 (75) |
| High-intensity conditioning regimens, no. (%) | |
| With TBI | 1730 (59) |
| Without TBI | 1137 (39) |
| With rabbit ATG | 74 (3) |
| GVHD prophylaxis, no. (%) | |
| Methotrexate with calcineurin inhibitors | 2394 (81) |
| Other | 547 (19) |
| Graft source, no. (%) | |
| Mobilized blood hematopoietic stem cells | 1014 (34) |
| Bone marrow | 1927 (66) |
| Donor type, no. (%) | |
| HLA-identical related | 1284 (44) |
| HLA-matched unrelated | 780 (26) |
| HLA-mismatched related | 270 (9) |
| HLA-mismatched unrelated | 607 (21) |
Low-risk diseases included CML in chronic phase; high-risk diseases included acute leukemia not in remission, CML in blast crisis, refractory anemia with excess blasts (RAEB), or RAEB in transformation and myeloma; all other diseases and stages were categorized as standard risk.